The study drew on the Island Study Linking Aging and Neurodegenerative Disease (ISLAND), a ten-year community-based initiative in Tasmania, Australia, that combines dementia education with large-scale data collection. From more than 1,300 potentially eligible participants, the researchers assembled a cross-sectional sample of 339 cognitively unimpaired adults with an average age of about 66 years, roughly 71 percent of them women. Of these, 238 reported no noticeable cognitive changes and served as asymptomatic controls, while 101 met criteria for subjective cognitive decline (SCD)—a self-perceived, persistent worsening of memory or mental function despite normal performance on cognitive tests. SCD matters because older adults with it progress to dementia at roughly twice the annual rate of those without it, and neuroimaging studies suggest it shares pathological features with mild cognitive impairment and Alzheimer’s dementia.

The participants completed the Tasmanian Test, a browser-based, self-administered battery of motor, cognitive, and speech tasks that they performed at home without supervision. For the speech component, they recorded four maximally paced DDK tasks in fixed order: rapid repetition of the monosyllables “pa,” “ta,” and “ka,” followed by the trisyllable sequence “pataka.” Each test lasted ten seconds, with up to two reattempts allowed. From the resulting audio recordings, the team extracted a rich set of features quantifying repetitions, speaking time, pauses, voice onset time—the interval between the release of a plosive consonant and the onset of vocal fold vibration—and variability measures. Crucially, they also computed derived “motor cost” measures by subtracting performance on one stimulus from another, capturing differences in articulatory control between bilabial, alveolar, and velar consonants, and between simple and complex sequences.

Why should rapid syllable repetition be sensitive to Alzheimer’s disease at all? The neurobiological rationale rests on the brain circuits that govern sub-second timing and sequential motor control. Functional MRI studies show that paced syllable repetition engages the putamen and cerebellum in a rate-dependent manner, and that rapid syllable-sequence production recruits the cerebellum in proportion to articulatory complexity. Cerebellar-basal ganglia circuits are central to internal timing and error correction, and Alzheimer’s-related alterations in cerebellar connectivity have been documented. Unlike connected speech tasks such as picture description, which confound motor control with language and memory demands, DDK tasks isolate the pure motor dimension of speech production—making them a potentially cleaner window onto preclinical brain changes.

The researchers tested whether these motor speech measures were associated with three established Alzheimer’s risk indicators: subjective cognitive decline, carriage of the apolipoprotein E ε4 allele, and plasma concentrations of phosphorylated tau 181 (p-tau181). Each carries weight. APOE ε4 is the strongest genetic risk factor for late-onset Alzheimer’s, conferring roughly three- to fourfold increased risk with one allele and eight- to fifteenfold with two. Plasma p-tau181 rises during preclinical disease, performs comparably to tau PET for classifying amyloid positivity in people with SCD, and predicts progression to Alzheimer’s dementia in cognitively unimpaired individuals. Blood samples had been collected at in-person clinics across Tasmania in 2021, with p-tau181 measured using an ultrasensitive single-molecule array platform and APOE genotype determined by PCR.

The statistical approach was deliberately cautious. Bivariate, nonparametric analyses with Benjamini-Hochberg correction for multiple comparisons found that no associations with SCD or APOE ε4 survived adjustment—only one measure, a “pa”-“ta” cost of repetition duration variability, remained significantly linked to plasma p-tau181. The team then turned to LASSO-penalized regression, a machine learning technique that shrinks coefficients to prevent overfitting in high-dimensional data. To stabilize estimates against the randomness of cross-validation fold assignment, they used a percentile-LASSO procedure, running each tenfold cross-validation process one hundred times and fitting the final model at the 95th percentile of the regularization parameter. Logistic models predicted SCD and APOE ε4 status, while a linear model predicted natural log-transformed p-tau181, with age, sex, education, anxiety, and depression available as covariates.

The results were intriguingly patterned. In the main analysis of 315 participants with complete data, motor speech measures predicted SCD with an area under the curve of 0.700, APOE ε4 carriage with an AUC of 0.715, and log-transformed p-tau181 with a mean absolute error of 0.323. For SCD, the simple models selected only depression as a predictor, but the more complex “maximal” models—which allowed interaction terms—consistently outperformed them and selected several motor speech features, always in interaction with depression. For APOE ε4, the simple models prevailed, with voice onset time features and variability measures prominent among the selected predictors, alongside age. For p-tau181, age was the only non-speech covariate chosen, and one derived measure in particular—voice onset time variability cost for “ka”-“pataka”—appeared in the superior model of every analysis, sometimes standing alone and sometimes interacting with age, education, and depression.

Depression emerged as a recurring complication. Because depression can affect subjective cognition, speech, and motor function alike, the researchers ran sensitivity analyses excluding participants with Hospital Anxiety and Depression Scale scores of eight or above, and separately incorporating hearing loss and expanded samples of participants with incomplete biomarker data. These analyses revealed potentially mitigating effects of depression and hints of bias from the limited availability of blood biomarker data. In the expanded sample, APOE ε4 prediction fell to barely better than chance in the full group, yet improved markedly in the low-depression subset, where more motor speech predictors were selected. The authors interpret this as evidence that depression may modify or obscure genuine relationships between motor speech control and Alzheimer’s risk factors, and that even subclinical depression may need explicit adjustment in future studies.

The study has clear limitations that the authors acknowledge candidly. It was cross-sectional and exploratory, so temporal direction cannot be established and longitudinal follow-up will be essential. The sample was predominantly White, highly educated women of Northern European ancestry, limiting generalizability, and participants were health-motivated volunteers in a dementia risk reduction program. Exclusion of cognitive impairment relied on self-reported diagnoses, and blood biomarker data were available only for those who attended clinics, introducing potential selection bias that the expanded-sample analyses could only partially address. The authors also note that the differencing process used to compute motor costs may reduce intra-individual variability, complicating interpretation of those derived measures.

Even with those caveats, the findings broaden the Alzheimer’s motor phenotype—which already includes slower gait, reduced stride length linked to p-tau181, and faster motor decline in APOE ε4 carriers—into the domain of speech motor control. If replicated with counter-balanced task order and longitudinal designs, motor speech measures could become scalable, non-invasive behavioral indicators that complement gait analysis and blood biomarkers in population screening. The vision is compelling: a browser-based test that anyone can take at home, extracting subtle signatures of articulatory timing and consistency that reflect the earliest biological whispers of Alzheimer’s disease. For now, the study stands as careful, early-stage evidence that the voice may know something about the brain that standard cognitive tests do not yet reveal.

Subject of Research: Associations between motor speech performance in rapid syllable repetition tasks and Alzheimer's disease risk markers in cognitively unimpaired older adults

Article Title: Motor speech markers of Alzheimer’s risk

Article References: Motor speech markers of Alzheimer’s risk. (n.d.). https://doi.org/10.1007/s11357-026-02560-w

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02560-w

Keywords: Alzheimer's disease, motor speech, diadochokinesis, subjective cognitive decline, APOE ε4, p-tau181, blood biomarkers, digital biomarkers, dementia screening, GeroScience, speech analysis, preclinical detection

The technology at the heart of the study is the OncoK9 test, a multi-cancer early detection assay developed by PetDx and clinically available for dogs since 2021. The test exploits the biology of circulating tumor DNA: as cancer cells grow and die, they shed fragments of DNA into the bloodstream. These cell-free DNA fragments carry somatic genomic alterations, acquired mutations and chromosomal changes that are hallmarks of malignancy. Using next-generation sequencing on blood drawn from a jugular or peripheral vein, the assay reads these fragments, aligns the sequences against the canine reference genome CanFam3.1, and applies custom bioinformatics pipelines to distinguish cancer-associated signals from background genomic noise. A result is returned to the veterinarian within seven to fourteen days, typically as a binary call: Cancer Signal Detected or Cancer Signal Not Detected.

Enrollment began in December 2021 under two institutional animal care protocols spanning 24 clinical sites across the United States and Canada, a mix of 21 general practices, two academic institutions and one specialty center. In total, 725 presumed cancer-free dogs joined the study, most of them classified as being at increased risk for cancer based on age, breed or body weight. Dogs aged seven years or older were eligible regardless of breed, as were younger dogs belonging to breeds with elevated lifetime cancer risk, and the cohort ranged in age from 1.75 to 20.2 years with a median of 8.4 years. Golden Retrievers dominated the breed list with 68 enrolled dogs, followed by Labrador Retrievers, German Shepherd Dogs, Boxers and Rottweilers. At each routine follow-up visit, conducted annually or every six months depending on the protocol, dogs received a complete physical examination and a blood draw of 14 to 17 milliliters collected into specialized tubes that keep cell-free DNA stable at ambient temperature for a week, requiring no refrigeration or immediate processing.

The first interim analysis focused on the 419 dogs that had been enrolled for at least a year with two or more screening visits, or that had received a cancer diagnosis while on study, with a mean observation period of 422 days. Within this group, 51 dogs were newly diagnosed with cancer, 37 with definitive diagnoses confirmed by pathologist-reviewed histopathology or cytology and 14 with presumptive diagnoses. The most common anatomic locations of disease were the liver, skin, bone, heart, spleen, lung and lymph nodes, a distribution that underscores why genomic screening matters: many of these cancers arise deep within the body where physical examination alone cannot detect them until they are advanced.

The performance metrics of the liquid biopsy test paint a nuanced picture. Of the 51 cancer-diagnosed dogs, 29 received a Cancer Signal Detected result, yielding an observed sensitivity, or detection rate, of 56.9 percent. Specificity was strikingly high at 98.9 percent, meaning only four dogs out of 366 that remained cancer-free received a false positive result, a false positive rate of just 1.1 percent. The positive predictive value reached 87.9 percent, indicating that nearly nine out of ten positive screening results were followed by an actual cancer diagnosis, and the negative predictive value was 94.3 percent. Notably, these figures closely match the test’s performance in its earlier clinical validation study and in a retrospective review of more than 1,500 real-world clinical cases, a consistency the authors attribute to the use of independent training and testing sets during validation, a design strategy intended to guard against statistical overfitting and inflated performance estimates.

Perhaps the most consequential finding concerns how cancer was actually detected. Under conventional veterinary practice, only 12 percent of the cancers in this cohort, six of 51 cases, were caught preclinically through wellness examinations or routine care alone, a figure consistent with a prior retrospective audit of more than 350 dogs in which just 4 percent of cancers were detected at routine visits. When the NGS-based test was added, workups prompted solely by a detected cancer signal led to the preclinical diagnosis of 22 additional cases, lifting the preclinical detection rate to 55 percent, a 4.6-fold increase. Overall, the test accounted for 26 of the 51 cancer diagnoses, effectively doubling the total number of cancers found in the population during the study period.

The clinical pathway following a positive result proved efficient and accessible. Among the 29 true-positive dogs, 86 percent had their first detected signal at a regularly scheduled visit rather than an unscheduled sick visit, and once a positive result triggered confirmatory evaluation, cancer was typically diagnosed within weeks, with a median time to diagnostic resolution of 23 days. More than half of these dogs reached diagnostic resolution within one month, and 92 percent within six months. Critically, in 27 of the 29 true-positive cases, cancer was localized using the diagnostics recommended in the study’s confirmatory evaluation, comprehensive physical exam, routine laboratory tests, three-view thoracic radiographs and abdominal ultrasound, all procedures commonly available in general practice, with only two dogs requiring advanced modalities such as echocardiography or magnetic resonance imaging. Among the 20 definitively diagnosed true-positive dogs, 14 had localized disease confined to the organ of origin, suggesting the test can identify cancer early enough to offer a genuine therapeutic window.

The study also documented rare false positives and a meaningful fraction of false negatives. The four false-positive dogs all underwent substantial confirmatory workups, including laboratory testing, thoracic and abdominal imaging, and in some cases echocardiography, fine needle aspiration or computed tomography, and none was diagnosed with cancer during continued follow-up. The authors caution, however, that some apparent false positives could represent ultra-early detection: human studies have retrospectively identified cancer-derived DNA alterations in plasma three to four years before clinical diagnosis, and the earlier CANDiD validation study reported detecting tumor-associated alterations five months before a hemangiosarcoma diagnosis in one dog. Longer follow-up, they note, will be needed to adjudicate such cases. Among the 22 false-negative dogs, more than a third carried small skin tumors under two centimeters, masses that the test was never intended to replace physical examination or fine needle aspiration in evaluating, and detection rates are known to vary with tumor size, extent of disease and anatomic location, with aggressive cancers like lymphoma and hemangiosarcoma more readily detectable than anatomically isolated tumors of the bladder, prostate or central nervous system.

Owner and veterinarian acceptance of the screening program was overwhelmingly positive. Of 343 owners who responded to satisfaction surveys, average agreement scores with statements about the value of annual or semi-annual screening hovered around 9.3 to 9.6 on a 10-point scale, and 297 of 343 respondents said they were likely or very likely to pay for recommended screening. Veterinarians rated the clarity of the test reports and their usefulness in clinical management at 9.5 or higher on average, though the survey response rate among clinicians was small, with only 10 of 44 questionnaires returned. Safety data were equally reassuring: of 725 enrolled dogs, just 35 adverse events were reported in connection with blood draws, nearly all minor hematomas or bruising at the venipuncture site, and no adverse events occurred during diagnostic workups prompted by positive results.

The study is not without limitations, and the authors are candid about them. The interim analysis covers a relatively short observation window, and key questions remain unresolved, including whether the optimal screening interval is six or twelve months, whether earlier detection ultimately improves stage-specific survival, and how to account for owners who self-select into longer screening intervals. Because dogs lack a standardized national cancer registry analogous to the SEER program in human oncology, precise canine cancer incidence remains uncertain, making the prospectively documented 12 percent period prevalence in this predominantly high-risk cohort a valuable new data point. The study was funded by PetDx, the test’s developer, and PetDx employees participated in the research. Still, the investigators frame CLASSiC as a milestone: the first evidence that incorporating genomic liquid biopsy into regularly scheduled wellness visits can substantially increase preclinical cancer detection in dogs, achieved with a simple blood collection that any clinical practice can perform, and a foundation for the evidence-based screening guidelines that veterinary medicine has long lacked.

Subject of Research: Prospective cancer screening in dogs using next-generation sequencing-based liquid biopsy

Article Title: The Cancer Lifetime Assessment Screening Study in Canines (CLASSiC): interim results of the first prospective cancer screening study in dogs using next-generation sequencing-based liquid biopsy

Article References: Flory, A., Gray, S., McLennan, L. M., Rafalko, J. M., Marshall, M. A., Wotrang, K., Kroll, M., Flesner, B. K., O’Kell, A. L., Cohen, T. A., Ruiz-Perez, C. A., Sandford, E., Clavere-Graciette, A., Phelps-Dunn, A., Motalli-Pepio, R., McCleary-Wheeler, A. L., Nakashe, P., Cristobal, M. A., Anderson, P., … Grosu, D. S. (2026). The Cancer Lifetime Assessment Screening Study in Canines (CLASSiC): interim results of the first prospective cancer screening study in dogs using next-generation sequencing-based liquid biopsy. Veterinary Oncology, 3(1), Article 12. https://doi.org/10.1186/s44356-026-00062-7

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00062-7

Keywords: canine cancer, liquid biopsy, next-generation sequencing, cancer screening, multi-cancer early detection, cell-free DNA, veterinary oncology, OncoK9, preclinical detection, CLASSiC study, prospective study, pet health